JPH075476B2
(ja)
*
|
1984-01-12 |
1995-01-25 |
ルッシュ、フォルケル |
ホルモン活性を有する生物学的作用物質、その製法およびヒストンの医薬的用途
|
US5994392A
(en)
|
1988-02-26 |
1999-11-30 |
Neuromedica, Inc. |
Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
|
US6830923B1
(en)
*
|
1989-03-16 |
2004-12-14 |
Boehringer Inglheim International Gmbh |
Genetics units for inhibiting the function of RNA
|
CA2063271A1
(en)
*
|
1989-07-14 |
1991-01-15 |
Subramonia Pillai |
Cytokine and hormone carriers for conjugate vaccines
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5624898A
(en)
|
1989-12-05 |
1997-04-29 |
Ramsey Foundation |
Method for administering neurologic agents to the brain
|
US6407061B1
(en)
*
|
1989-12-05 |
2002-06-18 |
Chiron Corporation |
Method for administering insulin-like growth factor to the brain
|
DE4000154A1
(de)
*
|
1990-01-04 |
1991-07-11 |
Symbiotec Gmbh |
Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen
|
US5545719A
(en)
*
|
1990-05-01 |
1996-08-13 |
Neuromedica, Inc. |
Nerve growth peptides
|
US5075288A
(en)
*
|
1990-09-05 |
1991-12-24 |
The University Of Tennessee Research Corporation |
Somnogenic fragment of interleukin-1β
|
US5780432A
(en)
*
|
1990-12-28 |
1998-07-14 |
Allegheny University Of The Health Sciences |
Therapeutic method for treatment of carcinoma or autoimmune diseases
|
US5189018A
(en)
*
|
1991-08-19 |
1993-02-23 |
Wayne State University |
Method for reduction of central nervous system (cns) edema resulting from head and spinal cord trauma
|
US5338837A
(en)
*
|
1991-12-13 |
1994-08-16 |
The Trustees Of Princeton University |
Glycosylated steroid derivatives for transport across biological membranes and process for making same
|
US5795870A
(en)
*
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
US5693769A
(en)
*
|
1991-12-13 |
1997-12-02 |
Transcell Technologies, Inc. |
Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
|
US5786158A
(en)
|
1992-04-30 |
1998-07-28 |
Yale University |
Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
|
US5981194A
(en)
*
|
1992-07-10 |
1999-11-09 |
University Of British Columbia |
Use of p97 and iron binding proteins as diagnostic and therapeutic agents
|
EP0599303A3
(de)
*
|
1992-11-27 |
1998-07-29 |
Takeda Chemical Industries, Ltd. |
Peptide-Konjugate
|
US5639866A
(en)
*
|
1993-02-23 |
1997-06-17 |
Princeton University |
Single-step formation of multiple glycosidic linkages
|
IL108748A0
(en)
*
|
1993-02-23 |
1994-08-26 |
Univ Princeton |
Solution and solid-phase formation of glycosidic linkages
|
ATE228832T1
(de)
*
|
1994-02-28 |
2002-12-15 |
Nanopharm Ag |
System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US6495526B2
(en)
*
|
1996-01-23 |
2002-12-17 |
Gpc Biotech, Inc. |
Inhibitors of cell-cycle progression and uses related thereto
|
US6576636B2
(en)
*
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
US5795909A
(en)
*
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
US5830850A
(en)
*
|
1996-08-28 |
1998-11-03 |
Mount Sinai School Of Medicine Of The City Of New York |
Methods for the treatment of bone resorption disorders, including osteoporosis
|
US6361938B1
(en)
*
|
1996-11-08 |
2002-03-26 |
Elan Corporation, Plc |
Peptides which enhance transport across tissues and methods of identifying and using the same
|
US6942963B1
(en)
|
1997-01-10 |
2005-09-13 |
Massachusetts Institute Of Technology |
Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
|
EP1015013A4
(de)
|
1997-01-10 |
2002-07-24 |
Massachusetts Inst Technology |
Behandlung von neurotoxizität in alzheimer'schen krankheit durch beta-amyloid peptiden
|
US5955355A
(en)
*
|
1997-03-27 |
1999-09-21 |
Millennium Pharmaceuticals, Inc. |
Chromosome 18 marker
|
US5914394A
(en)
*
|
1997-03-27 |
1999-06-22 |
Millenium Pharmaceuticals, Inc. |
Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
|
US5866412A
(en)
*
|
1997-03-27 |
1999-02-02 |
Millennium Pharmaceuticals, Inc. |
Chromosome 18 marker
|
US5939316A
(en)
*
|
1997-03-27 |
1999-08-17 |
Millennium Pharmaceuticals, Inc. |
Chromosome 18 marker
|
JP2001524824A
(ja)
|
1997-04-16 |
2001-12-04 |
ミレニアム・フアーマシユーチカルズ・インコーポレーテツド |
Crspタンパク質(システインに富む分泌性タンパク質)、それらをコードする核酸分子およびその用途
|
US6501188B1
(en)
*
|
1997-07-03 |
2002-12-31 |
Micron Technology, Inc. |
Method for improving a stepper signal in a planarized surface over alignment topography
|
US6225444B1
(en)
|
1998-02-10 |
2001-05-01 |
Protarga, Inc. |
Neuroprotective peptides and uses thereof
|
US20030077641A1
(en)
*
|
1998-03-11 |
2003-04-24 |
Laskowitz Daniel T. |
Methods of suppressing microglial activation and systemic inflammatory responses
|
US7205280B2
(en)
*
|
1998-03-11 |
2007-04-17 |
Cognosci, Inc. |
Methods of suppressing microglial activation
|
AU754436B2
(en)
|
1998-03-16 |
2002-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions for diagnosing and treating chromosome-18p related disorders
|
US6071737A
(en)
*
|
1998-03-16 |
2000-06-06 |
The Regents Of The University Of California |
Equine Neospora isolate and its uses
|
CA2323776C
(en)
|
1998-03-19 |
2010-04-27 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
DE1068357T1
(de)
|
1998-03-30 |
2001-07-19 |
Northwest Biotherapeutics Inc |
Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren
|
US6248528B1
(en)
|
1998-04-06 |
2001-06-19 |
Millennium Pharmaceuticals, Inc. |
Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
|
US20060088846A1
(en)
|
1998-08-28 |
2006-04-27 |
Michele Pagano |
Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
|
US7273618B2
(en)
*
|
1998-12-09 |
2007-09-25 |
Chiron Corporation |
Method for administering agents to the central nervous system
|
EP1161451A4
(de)
|
1999-02-26 |
2006-05-17 |
Human Genome Sciences Inc |
Menschliches alpha-endokin und verfahren zu seiner verwendung
|
EP1179000A4
(de)
|
1999-02-26 |
2005-10-12 |
Millennium Pharm Inc |
Ausscheidungsproteine und ihre verwendung
|
US7235583B1
(en)
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
US6716452B1
(en)
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
US7291714B1
(en)
|
1999-06-30 |
2007-11-06 |
Millennium Pharmaceuticals, Inc. |
Glycoprotein VI and uses thereof
|
WO2001014557A1
(en)
|
1999-08-23 |
2001-03-01 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
JP4027663B2
(ja)
*
|
1999-10-04 |
2007-12-26 |
ネクター セラピューティックス エイエル,コーポレイション |
ポリマー安定化神経ペプチド
|
EP1287162A2
(de)
|
1999-10-21 |
2003-03-05 |
Case Western Reserve University |
Ermittlung des genexpressionsprofils bei entzündlichen darmerkrankungen
|
CA2387805C
(en)
|
1999-11-18 |
2012-08-28 |
Corvas International, Inc. |
Nucleic acids encoding endotheliases, endotheliases and uses thereof
|
US6277974B1
(en)
|
1999-12-14 |
2001-08-21 |
Cogent Neuroscience, Inc. |
Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
|
US6894026B1
(en)
|
2000-01-11 |
2005-05-17 |
Atossa Healthcare, Inc. |
Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
|
US7700341B2
(en)
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
JP2003525038A
(ja)
*
|
2000-02-08 |
2003-08-26 |
ユニバーシティー オブ ブリティッシュ コロンビア |
治療薬をスクリーニングするための組成物および方法
|
WO2001064882A2
(en)
|
2000-02-29 |
2001-09-07 |
Millennium Pharmaceuticals, Inc. |
1983, 52881, 2398, 45449, 50289, and 52872, g protein-coupled receptors and uses therefor
|
KR100872884B1
(ko)
|
2000-03-24 |
2008-12-10 |
바이오스피어 메디칼 인코포레이티드 |
능동 색전화용 미소구
|
US20040110928A1
(en)
*
|
2000-04-12 |
2004-06-10 |
Andrea Crisanti |
Peptide conjugates for drug delivery
|
US7585497B2
(en)
|
2000-05-17 |
2009-09-08 |
Oregon Health & Science University |
Induction of apoptosis and cell growth inhibition by protein 4.33
|
EP1714661A3
(de)
|
2000-05-19 |
2012-03-14 |
The Center for Blood Research, INC. |
Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
|
US20030195707A1
(en)
*
|
2000-05-25 |
2003-10-16 |
Schork Nicholas J |
Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
|
US20020077775A1
(en)
*
|
2000-05-25 |
2002-06-20 |
Schork Nicholas J. |
Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
DK2042597T3
(da)
|
2000-06-23 |
2014-08-11 |
Genentech Inc |
Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
|
CA2709771A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
WO2003020200A2
(en)
*
|
2000-11-16 |
2003-03-13 |
New River Pharmaceuticals Inc. |
A novel pharmaceutical compound and methods of making and using same
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
WO2002051432A1
(en)
*
|
2001-11-16 |
2002-07-04 |
New River Pharmaceuticals Inc. |
A novel pharmaceutical compound and methods of making and using same
|
US20020099013A1
(en)
*
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
JP2003000268A
(ja)
|
2000-08-25 |
2003-01-07 |
Pfizer Prod Inc |
血管新生にかかわる疾患を診断および治療するための方法および組成物
|
AU8847801A
(en)
|
2000-08-25 |
2002-03-04 |
Basf Plant Science Gmbh |
Plant polynucleotides encoding novel prenyl proteases
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
WO2002034916A2
(en)
|
2000-10-27 |
2002-05-02 |
Oregon Health And Science University |
Novel mutant igbp-3 molecules that do not bind to igfs, but retain their ability to functionally bind igfbp-3 receptor
|
EP1341548A4
(de)
*
|
2000-11-03 |
2006-06-14 |
Massachusetts Inst Technology |
VERFAHREN ZUR IDENTIFIZIERUNG VON BEHANDLUNGEN GEGEN NEUROTOXIZITÄT BEI ALZHEIMER-KRANKHEIT, DIE DURCH $g(b)-AMYLOIDPEPTIDE HERVORGERUFEN WIRD
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
US8394813B2
(en)
*
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
NZ526617A
(en)
|
2000-11-28 |
2004-09-24 |
Wyeth Corp |
Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
|
PL365605A1
(en)
|
2000-11-28 |
2005-01-10 |
Wyeth |
Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
|
AU2002246580A1
(en)
*
|
2000-12-04 |
2002-07-24 |
The Regents Of The University Of California |
Antisense imaging of gene expression of the brain in vivo
|
ATE506075T1
(de)
|
2000-12-08 |
2011-05-15 |
Curagen Corp |
Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
|
AU2002241952A1
(en)
|
2001-01-22 |
2002-07-30 |
Genta Incorporated |
Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers
|
US7125703B2
(en)
|
2001-03-13 |
2006-10-24 |
Dendreon Corporation |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
US8231878B2
(en)
|
2001-03-20 |
2012-07-31 |
Cosmo Research & Development S.P.A. |
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
CA2441378A1
(en)
|
2001-03-22 |
2002-10-03 |
Dendreon San Diego Llc |
Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
|
AU2002305099A1
(en)
|
2001-03-23 |
2002-10-08 |
Protarga, Inc. |
Fatty alcohol drug conjugates
|
AU2002303164A1
(en)
*
|
2001-03-23 |
2002-10-08 |
Protarga, Inc. |
Fatty amine drug conjugates
|
WO2002077267A2
(en)
|
2001-03-27 |
2002-10-03 |
Dendreon San Diego Llc |
Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
|
MXPA03008959A
(es)
|
2001-04-02 |
2004-10-15 |
Wyeth Corp |
Pd-1, un receptor para b7-4 y sus usos.
|
US20040005309A1
(en)
*
|
2002-05-29 |
2004-01-08 |
Symbiontics, Inc. |
Targeted therapeutic proteins
|
US7629309B2
(en)
*
|
2002-05-29 |
2009-12-08 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
ATE384736T1
(de)
*
|
2001-04-30 |
2008-02-15 |
Zystor Therapeutics Inc |
Subzelluläres targeting von therapeutischen proteinen
|
US20070015144A9
(en)
*
|
2001-05-25 |
2007-01-18 |
Genset, S.A. |
Human cDNAs and proteins and uses thereof
|
US20040005543A1
(en)
|
2002-01-18 |
2004-01-08 |
Abraham Grossman |
Compositions and methods for binding agglomeration proteins
|
US20030096748A1
(en)
*
|
2001-06-04 |
2003-05-22 |
The Regents Of The University Of Michigan |
Methods and compositions for the treatment of diseases associated with signal transduction aberrations
|
EP2184359B1
(de)
|
2001-06-06 |
2016-03-02 |
Bioriginal Food & Science Corp. |
Samen-spezifische Promotoren aus Flachs (Linum usitatissimum L.)
|
EP1925671A1
(de)
|
2001-06-06 |
2008-05-28 |
Bioriginal Food & Science Corp. |
Flax-(Linum usitatissimum L.)-Samenspezifische Promotoren
|
CA2456571A1
(en)
*
|
2001-08-10 |
2003-02-20 |
Genset Sa |
Human secreted proteins, their encoding polynucleotides, and uses thereof
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
US7338939B2
(en)
*
|
2003-09-30 |
2008-03-04 |
New River Pharmaceuticals Inc. |
Abuse-resistant hydrocodone compounds
|
US7375082B2
(en)
*
|
2002-02-22 |
2008-05-20 |
Shire Llc |
Abuse-resistant hydrocodone compounds
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20070066537A1
(en)
*
|
2002-02-22 |
2007-03-22 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US7179617B2
(en)
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7399613B2
(en)
|
2001-10-10 |
2008-07-15 |
Neose Technologies, Inc. |
Sialic acid nucleotide sugars
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7265084B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
EP2292271A3
(de)
|
2001-10-10 |
2011-09-14 |
BioGeneriX AG |
Neumodulierung und Glykokonjugation von Antikörpern
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
EP2322229B1
(de)
|
2001-10-10 |
2016-12-21 |
Novo Nordisk A/S |
Neumodulierung und Glykokonjugation von Faktor IX
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US8008252B2
(en)
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7297511B2
(en)
|
2001-10-10 |
2007-11-20 |
Neose Technologies, Inc. |
Interferon alpha: remodeling and glycoconjugation of interferon alpha
|
WO2004099231A2
(en)
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7265085B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycoconjugation methods and proteins/peptides produced by the methods
|
US7226903B2
(en)
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
US7439043B2
(en)
|
2001-10-10 |
2008-10-21 |
Neose Technologies, Inc. |
Galactosyl nucleotide sugars
|
US20030072761A1
(en)
*
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
US7473680B2
(en)
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
EP1542719A4
(de)
|
2001-12-05 |
2006-06-21 |
Baylor College Medicine |
Verfahren und zusammensetzungen zur steuerung der knochenbildung über modulation des sympathikotonus
|
ES2528384T3
(es)
|
2001-12-12 |
2015-02-09 |
The Government Of The United States Of America, As Represented By The Secretary Department Of Healt |
Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación
|
AU2002366803A1
(en)
|
2001-12-19 |
2003-07-09 |
Millennium Pharmaceuticals, Inc. |
Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
|
AU2003219863C1
(en)
*
|
2002-02-22 |
2009-03-05 |
Shire Llc |
Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
|
US7659253B2
(en)
*
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
US7700561B2
(en)
*
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
US7105486B2
(en)
*
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
US7153685B2
(en)
|
2002-03-11 |
2006-12-26 |
The Board Of Trustees Of The University Of Illinois |
Tamoxifen and 4-hydroxytamoxifen-activated system for regulated production of proteins in eukaryotic cells
|
US7332585B2
(en)
*
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
WO2003086273A2
(en)
*
|
2002-04-08 |
2003-10-23 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Histone conjugates and uses thereof
|
US7074893B2
(en)
*
|
2002-06-03 |
2006-07-11 |
Regents Of The University Of Michigan |
Methods and compositions for the treatment of diseases associated with signal transduction aberrations
|
JP2006514823A
(ja)
|
2002-08-20 |
2006-05-18 |
ミレニアム ファーマスーティカルズ インク |
子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
|
EP1575518A4
(de)
|
2002-10-10 |
2007-08-22 |
Wyeth Corp |
Zusammensetzungen, organismen und methoden mit einer neuen humanen kinase
|
US7208306B2
(en)
|
2002-10-24 |
2007-04-24 |
Wyeth |
Compositions employing a novel human protein phosphatase
|
AU2003285200A1
(en)
*
|
2002-11-09 |
2004-06-03 |
Nobex Corporation |
Modified carbamate-containing prodrugs and methods of synthesizing same
|
WO2004045532A2
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Corporation |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
US7611839B2
(en)
|
2002-11-21 |
2009-11-03 |
Wyeth |
Methods for diagnosing RCC and other solid tumors
|
EP2112229A3
(de)
|
2002-11-25 |
2009-12-02 |
Sequenom, Inc. |
Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
|
US7388079B2
(en)
*
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
US20040102369A1
(en)
*
|
2002-11-27 |
2004-05-27 |
The Regents Of The University Of California |
Transport of basic fibroblast growth factor across the blood brain barrier
|
US7297525B2
(en)
|
2002-11-27 |
2007-11-20 |
Wyeth |
Composition employing a novel human kinase
|
JP5717937B2
(ja)
|
2002-12-06 |
2015-05-13 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
プロテアソーム阻害療法を用いた患者の同定、判定および治療方法
|
EP2298874A1
(de)
|
2002-12-16 |
2011-03-23 |
Halozyme, Inc. |
Humanes Chondrotinaseglykoprotein (CHASEGP), Verfahren zu dessen Herstellung und pharmazeutische Zusammensetzungen, die dieses umfassen
|
CA2511907A1
(en)
|
2003-01-06 |
2004-07-22 |
Wyeth |
Compositions and methods for diagnosing and treating colon cancers
|
DK1583562T3
(da)
*
|
2003-01-06 |
2011-09-19 |
Angiochem Inc |
Angiopep-1, beslægtede forbindelser og anvendelser deraf
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
PL1603541T5
(pl)
|
2003-03-05 |
2013-06-28 |
Halozyme Inc |
Rozpuszczalna glikoproteina o aktywności hialuronidazy (sHASEGP), sposób jej wytwarzania, zastosowanie i zawierające ją kompozycje farmaceutyczne
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
NZ542094A
(en)
|
2003-03-14 |
2008-12-24 |
Neose Technologies Inc |
Branched polymer conjugates comprising a peptide and water-soluble polymer chains
|
NZ607886A
(en)
|
2003-03-19 |
2014-09-26 |
Biogen Idec Inc |
Nogo receptor binding protein
|
EP1613261A4
(de)
|
2003-04-09 |
2011-01-26 |
Novo Nordisk As |
Intrazelluläre bildung von peptidkonjugaten
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
SI1624891T2
(sl)
|
2003-05-06 |
2013-09-30 |
Biogen Idec Hemophilia Inc. |
Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
AU2004240553A1
(en)
|
2003-05-09 |
2004-12-02 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of human growth hormone glycosylation mutants
|
AU2004251647B2
(en)
|
2003-05-29 |
2010-01-14 |
Takeda Pharmaceutical Company Limited |
Abuse resistant amphetamine compounds
|
CA2525236C
(en)
*
|
2003-06-20 |
2015-03-24 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
US20050026823A1
(en)
*
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
US20050221383A1
(en)
|
2003-08-08 |
2005-10-06 |
Choong-Chin Liew |
Osteoarthritis biomarkers and uses thereof
|
CA2539490A1
(en)
|
2003-09-18 |
2005-03-24 |
Genmab A/S |
Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer
|
EA008864B1
(ru)
*
|
2003-09-30 |
2007-08-31 |
Нью Ривер Фармасьютикалз Инк. |
Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
|
EP2051077A3
(de)
|
2003-10-07 |
2009-05-27 |
Millennium Pharmaceuticals, Inc. |
Nucleinsäuremoleküle und Proteine zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Eierstockkrebs
|
MXPA06005732A
(es)
|
2003-11-24 |
2006-08-17 |
Neose Technologies Inc |
Eritropoyetina glucopegilada.
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
ATE468356T1
(de)
|
2003-11-25 |
2010-06-15 |
Us Gov Health & Human Serv |
Mutierte anti-cd22-antikörper und immunkonjugate
|
US7956032B2
(en)
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
CN101072789B
(zh)
|
2004-01-08 |
2013-05-15 |
生物种属学股份公司 |
肽的o-连接的糖基化
|
WO2005070948A1
(en)
|
2004-01-23 |
2005-08-04 |
Intronn, Inc. |
Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing
|
US7968334B2
(en)
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
CN1922313B
(zh)
*
|
2004-02-10 |
2011-10-26 |
生物马林医药公司 |
酸性α-糖苷酶及其片段
|
EP1723177A2
(de)
|
2004-02-24 |
2006-11-22 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Rab9a, rab11a und modulatoren davon, die mit infektionskrankheiten in zusammenhang stehen
|
US20050272722A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20050277629A1
(en)
*
|
2004-03-18 |
2005-12-15 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies (Lansbury)
|
EP1732549A4
(de)
*
|
2004-03-18 |
2009-11-11 |
Brigham & Womens Hospital |
Verfahren zur behandlung von synucleinopathien
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
WO2005089504A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
DE602005022239D1
(de)
|
2004-04-23 |
2010-08-19 |
Conjuchem Biotechnologies Inc |
Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten
|
WO2005115435A2
(en)
|
2004-04-30 |
2005-12-08 |
Bas Medical, Inc. |
Methods and compositions for control of fetal growth via modulation of relaxin
|
AU2005243427B2
(en)
|
2004-05-04 |
2010-07-22 |
Novo Nordisk Health Care Ag |
O-linked glycoforms of polypeptides and method to manufacture them
|
WO2005117992A2
(en)
*
|
2004-05-30 |
2005-12-15 |
Cemines, Inc. |
Controlled delivery of therapeutic compounds
|
BRPI0512500A
(pt)
|
2004-06-24 |
2008-03-11 |
Biogen Idec Inc |
tratamento ou condições envolvendo desmielinação
|
US20080300173A1
(en)
|
2004-07-13 |
2008-12-04 |
Defrees Shawn |
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
|
CA2573720A1
(en)
|
2004-07-14 |
2006-02-23 |
University Of Utah Research Foundation |
Netrin-related compositions and uses
|
JP5060293B2
(ja)
|
2004-08-03 |
2012-10-31 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
神経機能におけるtaj
|
US8034762B2
(en)
*
|
2004-09-02 |
2011-10-11 |
Cognosci, Inc. |
Treatment of subarachnoid hemorrhage with Apo E analogs
|
WO2006029028A2
(en)
|
2004-09-02 |
2006-03-16 |
Cognosci, Inc. |
Improved apo e analogs and methods for their use
|
EP1799249A2
(de)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegyliertes interferon alpha
|
WO2006034296A2
(en)
|
2004-09-17 |
2006-03-30 |
Comentis, Inc. |
Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
|
JP5101288B2
(ja)
|
2004-10-05 |
2012-12-19 |
カリフォルニア インスティテュート オブ テクノロジー |
アプタマー調節される核酸及びその利用
|
US7871795B2
(en)
|
2004-10-08 |
2011-01-18 |
Virxsys Corporation |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
EP1831365B1
(de)
|
2004-10-08 |
2013-08-07 |
VIRxSYS Corporation |
Verwendung von rns trans-splicing zum antikörper gen transfer und zur antikörperherstellung
|
JP2008520191A
(ja)
|
2004-10-27 |
2008-06-19 |
バンダービルト・ユニバーシティ |
感染に関与する哺乳動物遺伝子
|
EP1814573B1
(de)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
US7517870B2
(en)
|
2004-12-03 |
2009-04-14 |
Fondazione Telethon |
Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
|
CA2593682C
(en)
|
2005-01-10 |
2016-03-22 |
Neose Technologies, Inc. |
Glycopegylated granulocyte colony stimulating factor
|
CA2599589A1
(en)
|
2005-02-07 |
2006-08-17 |
Genenews,Inc. |
Mild osteoarthritis biomarkers and uses thereof
|
AR052203A1
(es)
|
2005-02-09 |
2007-03-07 |
Bioriginal Food & Science Corp |
Nuevos miembros de la familia de desaturasa de acido graso omega - 3 y usos de estos
|
ES2383901T5
(es)
*
|
2005-02-18 |
2015-02-25 |
Angiochem Inc. |
Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro
|
JP2008535863A
(ja)
|
2005-04-08 |
2008-09-04 |
コメンティス,インコーポレーテッド |
β−セクレターゼ活性を阻害する化合物およびその使用方法
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
US8293477B2
(en)
|
2005-04-15 |
2012-10-23 |
Cornell University |
Methods for modulating bone formation and mineralization by modulating KRC activity
|
EP2305837A1
(de)
|
2005-05-11 |
2011-04-06 |
Aarhus Universitet |
Verfahren zur Diagnose und Behandlung einer Geisteskrankheit
|
EP1888098A2
(de)
|
2005-05-25 |
2008-02-20 |
Neose Technologies, Inc. |
Glykopegylierte erythropoetin-formulierungen
|
PT1904104E
(pt)
|
2005-07-08 |
2013-11-21 |
Biogen Idec Inc |
Anticorpos sp35 e suas utilizações
|
ES2424242T3
(es)
|
2005-07-15 |
2013-09-30 |
Angiochem Inc. |
Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
|
EP2311854B1
(de)
|
2005-07-29 |
2013-04-17 |
The Government of the United States of America, as represented by the Secretary of Health and Human Services |
Mutierte Pseudomonas Exotoxine mit reduzierter Antigenizität
|
PL1942932T3
(pl)
|
2005-08-08 |
2013-11-29 |
Univ Oregon Health & Science |
Inaktywacja patogenów nadtlenkiem wodoru do wytwarzania szczepionek
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
EP1957093B1
(de)
|
2005-08-29 |
2017-04-12 |
SHASHOUA, Victor E. |
Neuroprotektive und neurorestorative verfahren und zusammensetzungen
|
US20100130425A1
(en)
|
2005-09-09 |
2010-05-27 |
Oregon Health & Science University |
Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
|
TW200732347A
(en)
|
2005-10-06 |
2007-09-01 |
Trophogen Inc |
VEGF analogs and methods of use
|
US8053569B2
(en)
*
|
2005-10-07 |
2011-11-08 |
Armagen Technologies, Inc. |
Nucleic acids encoding and methods of producing fusion proteins
|
US8124095B2
(en)
*
|
2005-10-07 |
2012-02-28 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of erythropoietin to the CNS
|
US8741260B2
(en)
*
|
2005-10-07 |
2014-06-03 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of GDNF to the CNS
|
EP3037544A1
(de)
|
2005-10-13 |
2016-06-29 |
Human Genome Sciences, Inc. |
Verfahren und zusammensetzung zur verwendung bei der behandlung von systemisch lupus erythematosus patienten mit autoantikörper-positiven leiden
|
TW200730825A
(en)
|
2005-10-21 |
2007-08-16 |
Genenews Inc |
Method and apparatus for correlating levels of biomarker products with disease
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
KR20080080109A
(ko)
|
2005-11-04 |
2008-09-02 |
바이오겐 아이덱 엠에이 인코포레이티드 |
도파민성 뉴런의 신경돌기 성장 및 생존의 촉진 방법
|
WO2007053946A1
(en)
*
|
2005-11-09 |
2007-05-18 |
Conjuchem Biotechnologies Inc. |
Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
|
US9415107B2
(en)
|
2005-11-10 |
2016-08-16 |
Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College |
Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
|
US7807790B2
(en)
|
2005-11-14 |
2010-10-05 |
Metamol Theranostics, Llc |
Peptide sequence that promotes tumor invasion
|
EP1965827B1
(de)
|
2005-12-02 |
2015-02-25 |
Biogen Idec MA Inc. |
Behandlung von entmyelinisierenden erkrankungen
|
AU2006329215A1
(en)
*
|
2005-12-22 |
2007-06-28 |
Conjuchem Biotechnologies Inc. |
Process for the production of preformed conjugates of albumin and a therapeutic agent
|
CA2634598A1
(en)
|
2005-12-23 |
2007-07-05 |
Link Medicine Corporation |
Treatment of synucleinopathies
|
WO2007089601A2
(en)
|
2006-01-27 |
2007-08-09 |
Biogen Idec Ma Inc. |
Nogo receptor antagonists
|
WO2007091250A2
(en)
|
2006-02-06 |
2007-08-16 |
The Medical Research And Infrastructure Fund Of The Tel-Aviv Sourasky Medical Center |
Enzyme replacement therapy for treating lysosomal storage diseases
|
WO2007098607A1
(en)
|
2006-03-03 |
2007-09-07 |
Amorfix Life Sciences Ltd. |
Methods and compositions to treat and detect misfolded-sod1 mediated diseases
|
US7842299B2
(en)
|
2006-03-14 |
2010-11-30 |
Oregon Health & Science University |
Methods for producing an immune response to tuberculosis
|
US8277809B2
(en)
|
2006-04-21 |
2012-10-02 |
Centocor, Inc. |
CXCL13 antagonists and their use for the treatment of inflammatory diseases
|
US20070259820A1
(en)
*
|
2006-05-03 |
2007-11-08 |
The Regents Of The University Of Michigan |
Methods and reagents for activating heat shock protein 70
|
AU2007256780B2
(en)
|
2006-06-02 |
2013-08-29 |
President And Fellows Of Harvard College |
Protein surface remodeling
|
US8153369B2
(en)
|
2006-06-05 |
2012-04-10 |
Cancer Care Ontario |
Assessment of risk for colorectal cancer
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
JP2009544327A
(ja)
|
2006-07-21 |
2009-12-17 |
ノヴォ ノルディスク アー/エス |
O−結合型グリコシル化配列によるペプチドのグリコシル化
|
US8759297B2
(en)
*
|
2006-08-18 |
2014-06-24 |
Armagen Technologies, Inc. |
Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
|
US9308198B2
(en)
|
2006-09-08 |
2016-04-12 |
Rhode Island Hospital |
Treatment, prevention, and reversal of alcohol-induced brain disease
|
EP2054521A4
(de)
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
Verfahren zur reinigung von polypeptid-konjugate
|
AU2007319576B2
(en)
|
2006-10-06 |
2014-01-16 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Prevention of tissue ischemia, related methods and compositions
|
US8158595B2
(en)
|
2006-11-09 |
2012-04-17 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
CA2669347A1
(en)
*
|
2006-11-13 |
2008-05-29 |
Zystor Therapeutics, Inc. |
Methods for treating pompe disease
|
WO2008140493A2
(en)
*
|
2006-11-21 |
2008-11-20 |
The Regents Of The University Of Californina |
Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
US20080200441A1
(en)
*
|
2007-02-14 |
2008-08-21 |
University Of Southern California |
Estrogen receptor modulators associated pharmaceutical compositions and methods of use
|
AU2008221383B2
(en)
|
2007-02-28 |
2012-09-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Brachyury polypeptides and methods for use
|
EP2079839A4
(de)
|
2007-03-05 |
2009-11-18 |
Cancer Care Ontario |
Abschätzung des kolorektalkarzinomrisikos
|
US20090004213A1
(en)
*
|
2007-03-26 |
2009-01-01 |
Immatics Biotechnologies Gmbh |
Combination therapy using active immunotherapy
|
KR20150064246A
(ko)
|
2007-04-03 |
2015-06-10 |
바이오제너릭스 게엠베하 |
글리코페길화 g―csf를 이용하는 치료 방법
|
US9365634B2
(en)
*
|
2007-05-29 |
2016-06-14 |
Angiochem Inc. |
Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
|
ES2551123T3
(es)
|
2007-06-12 |
2015-11-16 |
Ratiopharm Gmbh |
Proceso mejorado para la producción de azúcares de nucleótido
|
AU2008282496B2
(en)
|
2007-07-27 |
2013-04-04 |
Armagen Technologies, Inc. |
Methods and compositions for increasing alpha-iduronidase activity in the CNS
|
US8367815B2
(en)
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
DK2197903T3
(en)
*
|
2007-09-04 |
2015-01-05 |
Us Gov Health & Human Serv |
Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
|
US8865667B2
(en)
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
CA2699787A1
(en)
|
2007-09-24 |
2009-04-02 |
Comentis, Inc. |
(3-hydroxy-4-amino-butan-2-yl)-3-(2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
|
US9029524B2
(en)
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
CN101514335B
(zh)
|
2008-02-22 |
2013-04-17 |
中国科学院生物物理研究所 |
流感病毒聚合酶亚基pa的表达纯化及pa氨基端及pa羧基端与pb1氨基端多肽复合体的晶体结构
|
CN101965200B
(zh)
|
2008-02-27 |
2013-06-19 |
诺沃-诺迪斯克有限公司 |
缀合的因子ⅷ分子
|
US8232402B2
(en)
*
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
JP5860698B2
(ja)
*
|
2008-04-18 |
2016-02-16 |
アンジオケム,インコーポレーテッド |
パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
|
JP2011523353A
(ja)
*
|
2008-04-28 |
2011-08-11 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
細胞透過のための過剰に荷電されたタンパク質
|
EP3778652A1
(de)
|
2008-05-07 |
2021-02-17 |
BioMarin Pharmaceutical Inc. |
Auf lysosomen gerichtete peptide und verwendungen davon
|
CA2729961C
(en)
|
2008-07-09 |
2018-05-01 |
Biogen Idec Ma Inc. |
Li113, li62 variant co2, anti-lingo antibodies
|
AU2010222930B2
(en)
|
2008-07-16 |
2013-07-25 |
Baylor Research Institute |
Antigen presenting cell targeted cancer vaccines
|
EP2151248A1
(de)
|
2008-07-30 |
2010-02-10 |
Johann Bauer |
Verbesserte Prä-mRNA-Trans-Splicing-Moleküle und deren Verwendungen
|
KR20110051245A
(ko)
|
2008-09-10 |
2011-05-17 |
제넨테크, 인크. |
안구 혈관신생의 억제 방법
|
BRPI0920209A2
(pt)
|
2008-10-15 |
2015-12-22 |
Angiochem Inc |
conjugados de agonistas de glp-1 e usos dos mesmos
|
RU2531591C2
(ru)
|
2008-10-15 |
2014-10-20 |
Ангиокем Инк. |
Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
|
US8476410B2
(en)
|
2008-10-16 |
2013-07-02 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
AU2009313927A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Astrazeneca Ab |
Azaquinolinone derivatives and uses thereof
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
CA2744016C
(en)
|
2008-11-20 |
2018-12-11 |
Cambria Pharmaceuticals, Inc. |
Treatment of amyotrophic lateral sclerosis
|
US9914754B2
(en)
*
|
2008-12-05 |
2018-03-13 |
Angiochem Inc. |
Conjugates of neurotensin or neurotensin analogs and uses thereof
|
MX2011006685A
(es)
|
2008-12-17 |
2011-09-27 |
Angiochem Inc |
Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
|
WO2010083338A2
(en)
|
2009-01-14 |
2010-07-22 |
Philadelphia Health And Education Corporation |
Modulation of pre-mrna using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
|
EP2389160B1
(de)
*
|
2009-01-23 |
2017-09-13 |
Evonik Corporation |
Kontinuierliches doppelemulsionsverfahren zur herstellung von mikroteilchen
|
CN101792745B
(zh)
|
2009-02-04 |
2014-09-17 |
中国科学院生物物理研究所 |
流感病毒聚合酶亚基pa氨基端多肽的表达纯化及pa氨基端多肽的晶体结构
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
US8664183B2
(en)
|
2009-02-27 |
2014-03-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
SPANX-B polypeptides and their use
|
CN102770457A
(zh)
|
2009-03-10 |
2012-11-07 |
贝勒研究院 |
靶向抗原呈递细胞的疫苗
|
CA2754862C
(en)
*
|
2009-03-10 |
2019-04-02 |
Baylor Research Institute |
Anti-cd40 antibodies and uses thereof
|
US9533055B2
(en)
|
2009-03-18 |
2017-01-03 |
Armagen Technologies, Inc. |
Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
ES2363358B1
(es)
|
2009-04-03 |
2012-06-21 |
FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al |
Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
|
ES2729261T3
(es)
|
2009-04-20 |
2019-10-31 |
Angiochem Inc |
Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
|
EP2427438B1
(de)
|
2009-05-05 |
2016-10-12 |
Cambria Pharmaceuticals, Inc. |
Pyrimidin-2,4,6-trione für die behandlung von amyotropher lateralsklerose
|
EP2438059A1
(de)
|
2009-06-05 |
2012-04-11 |
Link Medicine Corporation |
Aminopyrrolidinonderivate und ihre verwendung
|
US8785168B2
(en)
|
2009-06-17 |
2014-07-22 |
Biomarin Pharmaceutical Inc. |
Formulations for lysosomal enzymes
|
IN2012DN00248A
(de)
|
2009-07-02 |
2015-05-01 |
Angiochem Inc |
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
ES2354922B1
(es)
|
2009-09-02 |
2012-02-07 |
Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron |
Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
|
JP5795765B2
(ja)
|
2009-09-11 |
2015-10-14 |
アメリカ合衆国 |
低減した免疫原性を有する改良型シュードモナス(Pseudomonas)外毒素A
|
EP2480572B1
(de)
|
2009-09-25 |
2019-01-30 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralisierende antikörper gegen hiv-1 und ihre verwendung
|
HUE044865T2
(hu)
|
2009-10-09 |
2019-11-28 |
Armagen Inc |
Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
|
US9181306B2
(en)
|
2009-10-16 |
2015-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
EP2322149A1
(de)
|
2009-11-03 |
2011-05-18 |
Universidad del Pais Vasco |
Verfahren und Zusammensetzung zur Behandlung von Ischämie
|
CA2778953C
(en)
|
2009-11-13 |
2020-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
WO2011063263A2
(en)
|
2009-11-20 |
2011-05-26 |
Oregon Health & Science University |
Methods for producing an immune response to tuberculosis
|
CN104529945A
(zh)
|
2009-12-11 |
2015-04-22 |
基因密码公司 |
使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法
|
EP2338492A1
(de)
|
2009-12-24 |
2011-06-29 |
Universidad del Pais Vasco |
Verfahren und Zusammensetzung zur Behandlung von Alzheimer
|
WO2011088163A1
(en)
|
2010-01-14 |
2011-07-21 |
President And Fellows Of Harvard College |
Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
|
WO2011100455A1
(en)
|
2010-02-12 |
2011-08-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Inhibition of antibody responses to foreign proteins
|
WO2011112599A2
(en)
|
2010-03-12 |
2011-09-15 |
The United States Of America, As Represented By The Secretary. Department Of Health & Human Services |
Immunogenic pote peptides and methods of use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
EP2552947A4
(de)
|
2010-03-26 |
2013-11-13 |
Dartmouth College |
Vista-regulatorisches t-zellen-mediator-protein, vista-bindende wirkstoffe und verwendung davon
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
CN104689314B
(zh)
|
2010-06-16 |
2018-02-02 |
高等教育联邦系统-匹兹堡大学 |
内质蛋白的抗体及其用途
|
ES2377785B2
(es)
|
2010-09-08 |
2012-09-26 |
Universidad Miguel Hernández De Elche |
Composición farmacéutica para el tratamiento del ojo seco.
|
DK2626431T3
(en)
|
2010-10-06 |
2015-12-21 |
Fundació Inst De Recerca Biomèdica Irb Barcelona |
A process for the diagnosis, prognosis and treatment of breast cancer metastasis
|
EP2635906A4
(de)
|
2010-11-05 |
2014-04-02 |
Univ Brandeis |
Ice-hemmende verbindungen und ihre verwendungen
|
EP2646470B1
(de)
|
2010-11-30 |
2017-03-01 |
F. Hoffmann-La Roche AG |
Antikörper gegen transferin rezeptor mit niedriger affinität und ihre verwendungen zur überwindung der bluthirnschranke
|
WO2012102793A2
(en)
|
2010-12-10 |
2012-08-02 |
Zirus, Inc. |
Mammalian genes involved in toxicity and infection
|
WO2012095548A2
(es)
|
2011-01-13 |
2012-07-19 |
Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) |
Compuestos para el tratamiento de enfermedades neurodegenerativas
|
EP2680925B1
(de)
|
2011-03-02 |
2019-11-20 |
Berg LLC |
Interrogatorische zellbasierte assays und verwendung derselben
|
MX2013010185A
(es)
|
2011-03-10 |
2014-02-17 |
Genentech Inc |
Tratamiento de alteraciones con funcion de barrera vascular alterada.
|
CA2831294A1
(en)
|
2011-03-25 |
2012-10-04 |
Baylor Research Institute |
Compositions and methods to immunize against hepatitis c virus
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
WO2012145469A1
(en)
|
2011-04-19 |
2012-10-26 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies specific for glypican-3 and use thereof
|
EP2704688B1
(de)
|
2011-05-05 |
2019-07-10 |
Matinas BioPharma Nanotechnologies, Inc. |
Cochleatzusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
|
KR20140036216A
(ko)
|
2011-05-06 |
2014-03-25 |
더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 |
메소텔린을 표적화하는 재조합 면역독소
|
CA2837184C
(en)
|
2011-05-25 |
2021-09-21 |
Innate Pharma, S.A. |
Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
|
CN103764166B
(zh)
|
2011-06-22 |
2017-10-24 |
通用医疗公司 |
蛋白质病的治疗
|
AU2012284122B2
(en)
|
2011-07-18 |
2017-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods and compositions for inhibiting polyomavirus-associated pathology
|
WO2013011153A2
(en)
|
2011-07-21 |
2013-01-24 |
Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) |
Method for the prognosis and treatment of metastasis in breast cancer
|
AU2012298884B2
(en)
|
2011-08-23 |
2017-11-16 |
Foundation Medicine, Inc. |
Novel KIF5B-RET fusion molecules and uses thereof
|
WO2013039792A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunogens based on an hiv-1 gp120 v1v2 epitope
|
WO2013039880A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Biomarkers and therapeutic targets of hepatocellular cancer
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
US9783613B2
(en)
|
2011-10-04 |
2017-10-10 |
Igem Therapeutics Limited |
IgE anti-HMW-MAA antibody
|
WO2013055911A1
(en)
|
2011-10-14 |
2013-04-18 |
Dana-Farber Cancer Institute, Inc. |
Znf365/zfp365 biomarker predictive of anti-cancer response
|
EP3711778B1
(de)
|
2011-12-02 |
2024-05-08 |
Armagen, Inc. |
Verfahren und zusammensetzungen für erhöhte sulfatase-a-aktivität im zns
|
LT2814844T
(lt)
|
2012-02-15 |
2017-10-25 |
Novo Nordisk A/S |
Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
|
WO2013120554A1
(en)
|
2012-02-15 |
2013-08-22 |
Novo Nordisk A/S |
Antibodies that bind peptidoglycan recognition protein 1
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
EP2831277A4
(de)
|
2012-03-29 |
2016-06-29 |
Univ Colorado |
Klick-nucleinsäuren
|
SG10201608234UA
(en)
|
2012-04-02 |
2016-11-29 |
Berg Llc |
Interrogatory cell-based assays and uses thereof
|
WO2013152352A1
(en)
|
2012-04-06 |
2013-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Live, attenuated rubella vector to express vaccine antigens
|
EP2650682A1
(de)
|
2012-04-09 |
2013-10-16 |
Fundació Privada Institut de Recerca Biomèdica |
Asymmetrische Ester von als Schmiermittel geeigneten Fettsäuren
|
NZ702178A
(en)
|
2012-05-14 |
2017-01-27 |
Biogen Ma Inc |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
SG11201407972RA
(en)
|
2012-06-01 |
2015-01-29 |
Us Health |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
MX368513B
(es)
|
2012-06-06 |
2019-10-07 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
|
ES2434853B1
(es)
|
2012-06-12 |
2014-09-30 |
Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii |
Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
CA2877533C
(en)
|
2012-06-22 |
2022-08-16 |
The Trustees Of Dartmouth College |
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
|
EP2687852A1
(de)
|
2012-07-17 |
2014-01-22 |
Laboratorios Del. Dr. Esteve, S.A. |
Verfahren zur Diagnose und Behandlung des chronischen Erschöpfungssyndroms
|
US10457713B2
(en)
|
2012-07-30 |
2019-10-29 |
Trophogen, Inc. |
Glycoprotein hormone long-acting superagonists
|
CA3108181A1
(en)
|
2012-07-30 |
2014-02-06 |
Trophogen Inc. |
Glycoprotein hormone long-acting superagonists
|
AU2013296237B2
(en)
|
2012-08-03 |
2019-05-16 |
Foundation Medicine, Inc. |
Human papilloma virus as predictor of cancer prognosis
|
WO2014022759A1
(en)
|
2012-08-03 |
2014-02-06 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
CA2882753C
(en)
|
2012-08-21 |
2021-08-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
EP2892558B1
(de)
|
2012-09-07 |
2019-04-10 |
The Trustees Of Dartmouth College |
Vista-modulatoren zur diagnose und behandlung von krebs
|
EP2895191B1
(de)
|
2012-09-14 |
2019-06-05 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Brachyury-protein, adenovirale vektoren zur codierung von brachyury-protein und deren verwendung
|
EP2900695B1
(de)
|
2012-09-27 |
2018-01-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin-antikörper und verfahren zur auslösung einer starken antitumoraktivität
|
AU2013204200B2
(en)
|
2012-10-11 |
2016-10-20 |
Brandeis University |
Treatment of amyotrophic lateral sclerosis
|
WO2014057357A2
(en)
|
2012-10-12 |
2014-04-17 |
Inbiomotion S.L. |
Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
|
AU2013331328B2
(en)
|
2012-10-19 |
2018-05-31 |
Bavarian Nordic A/S |
Methods and compositions for the treatment of cancer
|
JP6386461B2
(ja)
|
2012-10-26 |
2018-09-05 |
エヌライフ、セラピューティックス、ソシエダッド、リミターダNlife Therapeutics, S.L. |
特定のニューロン種へのオリゴヌクレオチド分子の選択的送達によるパーキンソン病の治療のための組成物および方法
|
EP2914621B1
(de)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Neuartige ntrk1-fusionsmoleküle und verwendungen davon
|
US9775895B2
(en)
|
2012-12-12 |
2017-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HIV therapeutics and methods of making and using same
|
CN104994874B
(zh)
|
2012-12-26 |
2017-04-12 |
安科协同公司 |
抗整联蛋白β1抗体组合物及其使用方法
|
US9856474B2
(en)
|
2013-01-16 |
2018-01-02 |
Iowa State University Research Foundation, Inc. |
Deep intronic target for splicing correction on spinal muscular atrophy gene
|
WO2014113729A2
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Mecicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014122275A1
(en)
|
2013-02-08 |
2014-08-14 |
Fundación Pública Andaluza Progreso Y Salud |
Method for the diagnosis and monitoring of autoinmune diseases
|
EP2956169B1
(de)
|
2013-02-12 |
2018-04-11 |
THE UNITED STATES OF AMERICA, represented by the S |
Monoklonale antikörper zur neutralisierung von noroviren
|
EP2968536B1
(de)
|
2013-03-13 |
2023-06-28 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Verfahren zur modulierung von chemotherapeutischer zytotoxizität
|
BR112015023783A2
(pt)
|
2013-03-15 |
2017-10-24 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
método para diagnóstico e tratamento de metastase no câncer
|
MX368575B
(es)
|
2013-03-15 |
2019-10-08 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia personalizada de metástasis de cáncer de mama.
|
WO2014184679A2
(en)
|
2013-03-15 |
2014-11-20 |
Inbiomotion S.L. |
Method for the prognosis and treatment of renal cell carcinoma metastasis
|
WO2014182532A1
(en)
|
2013-05-07 |
2014-11-13 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Mesothelin-specific immunocytokine and use thereof
|
EP2994163B1
(de)
|
2013-05-09 |
2019-08-28 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Single-domain-vhh-antikörper gegen norovirus gi.1 und gii.4 und deren verwendung
|
EP3004877A4
(de)
|
2013-06-06 |
2017-04-19 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzungen und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
|
TR201904121T4
(tr)
|
2013-07-09 |
2019-04-22 |
The Government Of The United States As Represented By The Secretary Of The Dept Of Health And Human |
İnsan bispesifik egfrviii antikoru birleştirme molekülleri.
|
AU2014290044B2
(en)
|
2013-07-17 |
2020-10-29 |
Foundation Medicine, Inc. |
Methods of treating urothelial carcinomas
|
CA2919477A1
(en)
|
2013-07-31 |
2015-02-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
|
EP3043790B1
(de)
|
2013-09-11 |
2021-05-26 |
The Administrators of the Tulane Educational Fund |
Neuartige anthranilamide und verwendung davon
|
WO2015036643A2
(es)
|
2013-09-13 |
2015-03-19 |
Sierra Jiménez Angels |
Marcador para predecir metástasis del cancer de mama
|
EP3049442A4
(de)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Verfahren zur behandlung von blutkrebs
|
MX362041B
(es)
|
2013-10-09 |
2019-01-07 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
|
JP6502931B2
(ja)
|
2013-10-11 |
2019-04-17 |
アメリカ合衆国 |
Tem8抗体およびその使用
|
CN105899223A
(zh)
|
2013-10-28 |
2016-08-24 |
加利福尼亚大学董事会 |
转移性前列腺癌的治疗
|
EP3065766A1
(de)
|
2013-11-05 |
2016-09-14 |
Trophogen Inc. |
Langwirkende glykoproteinhormon-superagonisten
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
US9931393B2
(en)
|
2013-12-20 |
2018-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunogenic JC polyomavirus compositions and methods of use
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
ES2920677T3
(es)
|
2013-12-24 |
2022-08-08 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-VISTA
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
WO2015106003A1
(en)
|
2014-01-08 |
2015-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Ras pathways as markers of protection against hiv and methods to improve vaccine efficacy
|
EP3992210A1
(de)
|
2014-01-13 |
2022-05-04 |
Baylor Research Institute |
Neuartige impfstoffe gegen hpv und hpv-assoziierte erkrankungen
|
US10323083B2
(en)
|
2014-01-15 |
2019-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Agents that specifically bind matrilin-3 and their use
|
AU2015249374A1
(en)
|
2014-04-24 |
2016-12-01 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
WO2015175704A1
(en)
|
2014-05-14 |
2015-11-19 |
The Regents Of The University Of California |
Inhibitors of bacterial dna gyrase with efficacy against gram-negative bacteria
|
EP3154585B1
(de)
|
2014-06-11 |
2022-02-23 |
Kathy A. Green |
Verwendung von vista-agonisten und antagonisten zur unterdrückung oder verbesserung der humoralen immunität
|
MY178347A
(en)
|
2014-07-17 |
2020-10-08 |
Novo Nordisk As |
Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
|
US9683017B2
(en)
|
2014-07-17 |
2017-06-20 |
University Tennessee Research Foundation |
Inhibitory peptides of viral infection
|
JP6811706B2
(ja)
|
2014-07-31 |
2021-01-13 |
ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー |
Epha4に対するヒトモノクローナル抗体及びそれらの使用
|
WO2016027168A2
(en)
|
2014-08-20 |
2016-02-25 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof
|
CA2956820A1
(en)
|
2014-08-26 |
2016-03-03 |
University Of Tennessee Research Foundation |
Targeting immunotherapy for amyloidosis
|
US10400015B2
(en)
|
2014-09-04 |
2019-09-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant HIV-1 envelope proteins and their use
|
AU2015328411C1
(en)
|
2014-10-06 |
2022-03-03 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
US10300073B2
(en)
|
2014-10-14 |
2019-05-28 |
The Regents Of The University Of California |
Use of CDK9 and BRD4 inhibitors to inhibit inflammation
|
EP3875481A1
(de)
|
2014-11-14 |
2021-09-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neutralisierende antikörper gegen ebola-virus-glycoprotein und deren verwendung
|
US10072070B2
(en)
|
2014-12-05 |
2018-09-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Potent anti-influenza A neuraminidase subtype N1 antibody
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
AU2015360903B2
(en)
|
2014-12-08 |
2021-03-25 |
Dana-Farber Cancer Institute, Inc. |
Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
|
EP3236998A1
(de)
|
2014-12-24 |
2017-11-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Rekombinante metapneumovirusproteine und deren verwendung
|
JP2018504400A
(ja)
|
2015-01-08 |
2018-02-15 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Lingo‐1拮抗薬及び脱髄障害の治療のための使用
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
KR20170140180A
(ko)
|
2015-02-24 |
2017-12-20 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
|
US10487324B2
(en)
|
2015-02-25 |
2019-11-26 |
Washington University |
Methods to detect motor neuron disease comprising micro-RNAs
|
WO2016144673A1
(en)
|
2015-03-06 |
2016-09-15 |
Dana-Farber Cancer Institute, Inc. |
Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
|
US20180042998A1
(en)
|
2015-03-10 |
2018-02-15 |
University Of Massachusetts |
Targeting gdf6 and bmp signaling for anti-melanoma therapy
|
CN107614062A
(zh)
|
2015-03-12 |
2018-01-19 |
加利福尼亚大学董事会 |
用RORγ抑制剂治疗癌症的方法
|
US10562960B2
(en)
|
2015-03-20 |
2020-02-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to gp120 and their use
|
US20180156807A1
(en)
|
2015-04-29 |
2018-06-07 |
New York University |
Method for treating high-grade gliomas
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
EP3307877B1
(de)
|
2015-06-12 |
2020-11-18 |
Lentigen Technology, Inc. |
Verfahren zur behandlung von krebs mit veränderten t-zellen
|
ES2826827T3
(es)
|
2015-06-15 |
2021-05-19 |
Angiochem Inc |
Métodos para el tratamiento de carcinomatosis leptomeníngea
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
WO2017062820A1
(en)
|
2015-10-09 |
2017-04-13 |
Miltenyi Biotec Technology, Inc. |
Chimeric antigen receptors and methods of use
|
EP3362074B1
(de)
|
2015-10-16 |
2023-08-09 |
President and Fellows of Harvard College |
Pd-1-modulation in regulatorischen t-zellen zur regulierung von t-zelleffektorimmunreaktionen
|
US20210106661A1
(en)
|
2015-10-29 |
2021-04-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
|
US11236152B2
(en)
|
2015-11-03 |
2022-02-01 |
The United States of America, as represented by the Sectetary, Department of Health and Human Services |
Neutralizing antibodies to HIV-1 GP41 and their use
|
TWI756204B
(zh)
|
2016-02-12 |
2022-03-01 |
比利時商楊森製藥公司 |
抗vista抗體及片段、其用途及鑑定其之方法
|
WO2017151517A1
(en)
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
JP2019512271A
(ja)
|
2016-03-21 |
2019-05-16 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
T細胞疲弊状態特異的遺伝子発現調節因子およびその使用
|
CN118108843A
(zh)
|
2016-04-15 |
2024-05-31 |
伊穆奈克斯特股份有限公司 |
抗人vista抗体及其用途
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
CA3022603A1
(en)
|
2016-05-10 |
2017-11-16 |
Najit Technologies, Inc. |
Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
WO2018022904A2
(en)
|
2016-07-27 |
2018-02-01 |
Case Western Reserve University |
Compounds and methods of promoting myelination
|
EP3494135A1
(de)
|
2016-08-02 |
2019-06-12 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Gegen glypican-2 (gpc2) gerichtete monoklonale antikörper und verwendung davon
|
US11453712B2
(en)
|
2016-09-02 |
2022-09-27 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with DuoCARs
|
JP7466308B2
(ja)
|
2016-09-20 |
2024-04-12 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Usp10バイオマーカーおよびモジュレーターを用いたamlの同定、評価、予防および処置のための組成物および方法
|
WO2018071576A1
(en)
|
2016-10-14 |
2018-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Treatment of tumors by inhibition of cd300f
|
EP4276187A3
(de)
|
2016-12-08 |
2024-01-17 |
Case Western Reserve University |
Verfahren und zusammensetzungen zur erhöhung der herstellung von funktionalem myelin
|
MX2019006349A
(es)
|
2016-12-16 |
2019-08-22 |
Inst Res Biomedicine |
Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
|
AU2017382883A1
(en)
|
2016-12-21 |
2019-06-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
AU2018205372B2
(en)
|
2017-01-09 |
2020-08-06 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
WO2018148660A1
(en)
|
2017-02-10 |
2018-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
BR112019018700A2
(pt)
|
2017-03-10 |
2020-04-07 |
Embera Neurotherapeutics Inc |
composições farmacêuticas e seus usos
|
CN112695050A
(zh)
|
2017-03-24 |
2021-04-23 |
莱蒂恩技术公司 |
用于用抗cd33免疫疗法治疗癌症的组合物和方法
|
CA3058457A1
(en)
|
2017-03-31 |
2018-10-04 |
Seattle Genetics, Inc. |
Combinations of chk1- and wee1 - inhibitors
|
WO2018201016A1
(en)
|
2017-04-28 |
2018-11-01 |
Cascadian Therapeutics, Inc. |
Treatment of her2 positive cancers
|
EP3625256A1
(de)
|
2017-05-19 |
2020-03-25 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Humaner monoklonaler antikörper gegen tnfr2 zur krebsimmuntherapie
|
US11820822B2
(en)
|
2017-06-06 |
2023-11-21 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
CN111183156A
(zh)
|
2017-07-31 |
2020-05-19 |
莱蒂恩技术公司 |
用于用抗cd19/cd20免疫治疗来治疗癌症的组合物和方法
|
GB201712952D0
(en)
|
2017-08-11 |
2017-09-27 |
Univ Edinburgh |
Immunomodulatory agent
|
EP4279086A3
(de)
|
2017-09-15 |
2024-02-28 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd19-immuntherapie
|
US10610585B2
(en)
|
2017-09-26 |
2020-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating and preventing HIV
|
EP4279584A3
(de)
|
2017-10-16 |
2024-03-06 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd22-immuntherapie
|
EP3703745B1
(de)
|
2017-11-04 |
2024-04-10 |
Nevada Research & Innovation Corporation |
Immunogene konjugate und verfahren zur verwendung davon
|
CN111954677A
(zh)
|
2017-12-20 |
2020-11-17 |
莱蒂恩技术公司 |
用于用免疫治疗来治疗hiv/aids的组合物和方法
|
US11976109B2
(en)
|
2018-01-02 |
2024-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
EP3755713A1
(de)
|
2018-02-21 |
2020-12-30 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralisierende antikörper gegen hiv-1-env und deren verwendung
|
PE20201343A1
(es)
|
2018-04-02 |
2020-11-25 |
Bristol Myers Squibb Co |
Anticuerpos anti-trem-1 y usos de los mismos
|
WO2019236590A1
(en)
|
2018-06-04 |
2019-12-12 |
University Of Maryland, Baltimore |
Methods for preventing acute kidney injury
|
AU2019301675A1
(en)
|
2018-07-12 |
2021-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured CD22-specific monoclonal antibody and uses thereof
|
WO2020033430A1
(en)
|
2018-08-08 |
2020-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
WO2020033791A1
(en)
|
2018-08-09 |
2020-02-13 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
CA3113058A1
(en)
|
2018-09-20 |
2020-03-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd123 immunotherapy
|
EP3856235A2
(de)
|
2018-09-26 |
2021-08-04 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd19/cd22-immuntherapie
|
WO2020097261A1
(en)
|
2018-11-06 |
2020-05-14 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
New compositions and methods for treating beta-globinopathies
|
JP2022513682A
(ja)
|
2018-11-30 |
2022-02-09 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd38免疫療法によりがんを処置するための組成物および方法
|
US20220031830A1
(en)
|
2018-12-04 |
2022-02-03 |
The Rockefeller University |
Hiv vaccine immunogens
|
WO2020132214A2
(en)
|
2018-12-20 |
2020-06-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
US20220064324A1
(en)
|
2019-01-08 |
2022-03-03 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting mesothelin for treating solid tumors
|
WO2020154150A1
(en)
|
2019-01-22 |
2020-07-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
TW202042820A
(zh)
|
2019-01-28 |
2020-12-01 |
美商西雅圖遺傳學股份有限公司 |
以妥卡替尼(Tucatinib)治療乳癌之方法
|
CA3132660A1
(en)
|
2019-03-06 |
2020-09-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
US20220289854A1
(en)
|
2019-04-30 |
2022-09-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
EP3976653A1
(de)
|
2019-05-30 |
2022-04-06 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-bcma-immuntherapie
|
CN114269783B
(zh)
|
2019-07-02 |
2024-03-26 |
美国政府(由卫生和人类服务部的部长所代表) |
结合egfrviii的单克隆抗体及其应用
|
MX2022004699A
(es)
|
2019-10-21 |
2022-08-08 |
Seagen Inc |
Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab.
|
US20220380471A1
(en)
|
2019-10-22 |
2022-12-01 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7-h3 (cd276) for treating multiple solid tumors
|
EP4058024A1
(de)
|
2019-11-15 |
2022-09-21 |
Seagen Inc. |
Verfahren zur behandlung von her2-positivem brustkrebs mit tucatinib in kombination mit einem anti-her2-antikörper-wirkstoff-konjugat
|
EP4041769A1
(de)
|
2019-12-12 |
2022-08-17 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Antikörper-wirkstoff-konjugate spezifisch für cd276 und deren verwendungen
|
WO2021154705A1
(en)
|
2020-01-27 |
2021-08-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
|
EP4093762A1
(de)
|
2020-02-20 |
2022-11-30 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoklonale epstein-barr-virus-antikörper und verwendungen davon
|
CA3174986A1
(en)
|
2020-03-11 |
2021-09-16 |
Seagen Inc. |
Methods of treating her2 mutant cancers with tucatinib
|
WO2021262723A1
(en)
|
2020-06-22 |
2021-12-30 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
EP4192952A1
(de)
|
2020-08-10 |
2023-06-14 |
Novartis AG |
Behandlungen für degenerative netzhauterkrankungen
|
CN116437924A
(zh)
|
2020-09-28 |
2023-07-14 |
思进股份有限公司 |
用妥卡替尼与抗her2抗体的组合治疗her2改变驱动的实体瘤的方法
|
WO2022093745A1
(en)
|
2020-10-26 |
2022-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
CA3171093A1
(en)
|
2020-11-05 |
2022-05-12 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
CA3200671A1
(en)
|
2020-11-17 |
2022-05-27 |
Seagen Inc. |
Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
CA3208365A1
(en)
|
2021-02-15 |
2022-08-18 |
Chantal KUHN |
Cell therapy compositions and methods for modulating tgf-b signaling
|
WO2022187440A1
(en)
|
2021-03-03 |
2022-09-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
La protien as a novel regulator of osteoclastogenesis
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
WO2022240824A1
(en)
|
2021-05-13 |
2022-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for treating sickle cell diseases
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
CA3216228A1
(en)
|
2021-06-09 |
2022-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
WO2023281097A1
(en)
|
2021-07-09 |
2023-01-12 |
Immunic Ag |
Methods for treating cancer
|
WO2023076881A1
(en)
|
2021-10-26 |
2023-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
WO2023192827A1
(en)
|
2022-03-26 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to hiv-1 env and their use
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
WO2023201333A1
(en)
|
2022-04-14 |
2023-10-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to ebola virus glycoprotein and their use
|
WO2023230429A1
(en)
|
2022-05-22 |
2023-11-30 |
Seagen Inc. |
Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|
WO2024079662A1
(en)
|
2022-10-11 |
2024-04-18 |
Meiragtx Uk Ii Limited |
Upf1 expression constructs
|